Sotera Health (NASDAQ:SHC) Receives Outperform Rating from Royal Bank of Canada

Sotera Health (NASDAQ:SHC)‘s stock had its “outperform” rating reiterated by stock analysts at Royal Bank of Canada in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $17.00 price objective on the stock. Royal Bank of Canada’s price objective indicates a potential upside of 32.81% from the company’s current price.

A number of other brokerages also recently issued reports on SHC. Barclays upped their price target on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, August 6th. Citigroup upped their target price on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Sotera Health Stock Down 3.1 %

Sotera Health stock traded down $0.41 during mid-day trading on Thursday, hitting $12.80. The company had a trading volume of 238,087 shares, compared to its average volume of 1,300,829. Sotera Health has a 12 month low of $10.71 and a 12 month high of $17.44. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The stock’s 50 day moving average price is $15.77 and its two-hundred day moving average price is $13.94. The company has a market capitalization of $3.63 billion, a PE ratio of 51.48 and a beta of 2.08.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million for the quarter, compared to analysts’ expectations of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the company posted $0.18 earnings per share. As a group, sell-side analysts anticipate that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the transaction, the director now directly owns 49,215,301 shares of the company’s stock, valued at approximately $739,705,974.03. This trade represents a 16.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 55.12% of the company’s stock.

Institutional Trading of Sotera Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. William Blair Investment Management LLC grew its stake in shares of Sotera Health by 0.6% during the 2nd quarter. William Blair Investment Management LLC now owns 1,131,455 shares of the company’s stock valued at $13,430,000 after acquiring an additional 6,707 shares during the period. Clearline Capital LP purchased a new stake in shares of Sotera Health in the second quarter worth $1,707,000. First Pacific Advisors LP purchased a new position in shares of Sotera Health during the 2nd quarter valued at $540,000. Darsana Capital Partners LP bought a new position in Sotera Health in the 2nd quarter worth $29,074,000. Finally, Bank of New York Mellon Corp increased its stake in Sotera Health by 3.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,004,046 shares of the company’s stock worth $11,918,000 after buying an additional 37,681 shares in the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.